Investment
Features
FeesSafety
Academy
More
Pluang+

Compare J M Smucker Co (SJM) vs Summit Therapeutics Inc (SMMT) Price & Performance

J M Smucker CoTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

J M Smucker Co vs Summit Therapeutics Inc — how do they compare? J M Smucker Co trades at $112.69 (market cap $11.97B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: J M Smucker Co and Summit Therapeutics Inc are close in size by market cap, and J M Smucker Co pays a 3.93% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

SJMSMMT
Market Cap
$11.97B$10.48B
Sector
Consumer StaplesHealth
52-Week High
$117.05$29.32
52-Week Low
$89.53$13.05
Enterprise Value
$19.00B$9.90B
Dividend Yield
3.93%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About J M Smucker Co

J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.

Read more on SJM

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT